natgillin/translations-raw huggingface dataset:
Proportion of subjects (%)
Delež bolnikov (%)
Proportion of subjects achieving a post-vaccination titer ≥1:40
Razmerje oseb, ki imajo po cepljenju titer ≥ 1 : 40
Proportion of subjects achieving a post-vaccination titer ≥1:40
Razmerje oseb, ki so dosegli po cepljenju titer ≥ 1 : 40
Proportion of subjects relapsed
Delež oseb z recidivom
Proportion of subjects that achieved
≥ 1 g/dl (%)
Proportion of subjects with HIV-1 RNA < 50 copies/ml at
Odstotek preiskovancev s HIV-1 RNK < 50 kopij/ml v
Proportion of Subjects Without On-study SRE
Delež bolnikov brez SRE med študijo
Proportion of tumour M- that are M- by ctDNA)
Delež tumorskih M-, ki so M- po ctDNK)
Proportion of women with fracture (%)
Delež žensk z zlomom (%)
Proportion progressed1(12-week confirmation; primary outcome)
Delež napredovanja1 (potrditev po 12 tednih; primarni izid)
Proportion relapsed
Razmerje tveganj
PROPORTION RESPONDERS
DELEŽ BOLNIKOV Z ODZIVOM
Proportion undetectable (<300 copies/ml)b
Delež nedokazljivih (<300 kopij/ml)b
Proportion with 12-week confirmed disability progression
Delež z 12-tedenskim potrjenim napredovanjem bolezni
Proportion with 24 week confirmed disability progression
Delež s 24-tedenskim potrjenim napredovanjem bolezni
Proportion with 3-month Confirmed Disability Progression†
delež bolnikov z napredovanjem invalidnosti, ugotovljenim po 3 mesecih
Proportion with ferritin
Delež z vrednostjo feritina
Proportiona in Mozobil and G-CSF (n=144b)
delež a v skupini Mozobil in G-CSF (n = 144 b)
Proportiona in Mozobil and G-CSF (n=147b)
delež a v skupini Mozobil in G-CSF (n = 147 b)
Proportiona in Placebo and G-CSF (n=142b)
delež a v skupini placebo in G-CSF (n = 142 b)
Proportional increases of the plasma concentration were observed for doses from 2 – 60 mg.
Za odmerke od 2 do 60 mg so opažali sorazmerna povišanja plazemskih koncentracij.
Proportional increases of the plasma concentration were observed for doses from 2–60 mg.
Za odmerke od 2 do 60 mg so opažali sorazmerna povišanja plazemskih koncentracij.
Proportional increases of the serum concentration were observed for doses from 2-60 mg.
Pri odmerkih od 2 do 60 mg so opazili sorazmerna povečanja koncentracije v serumu.
Proportional reporting ratio (PRR), Information Component (IC) or the Empirical Bayesian Geometric Mean (EBMG)); this is not mandatory as all MAHs do not yet have this capability.
Proportional reporting ratio (PRR), Information Component (IC) ali Empirical Bayesian Geometric Mean (EBMG)); to ni obvezno, saj vsi imetniki dovoljenja za promet še nimajo te možnosti.
Proportions of patients achieving HbA1c <7% targets (%)
Deleži bolnikov, ki so dosegli ciljno vrednost HbA1c < 7 % (%)
Proportions of patients in GINA steps 4 and 5c
Delež bolnikov s 4. in
Proportions with HIV-1 RNA < 50 copies/ml (50% versus 47%) and < 400 copies/ml (54% versus 57%) at week 48 were also similar in each group (ITT population).
V obeh skupinah (vključena populacija) je bil po 48 tednih ugotovljen tudi podoben odstotek HIV-1 RNA < 50 kopij/ml (50 % versus 47 %) in < 400 kopij/ml (54 % versus 57 %).
Proportions with HIV-1 RNA < 50 copies/ml (50% versus 47%) and < 400 copies/ml (54% versus 57%) were also similar in each group (ITT population).
V obeh skupinah (vsi vključeni bolniki) je bil ugotovljen tudi podoben odstotek HIV-1 RNA < 50 kopij/ml (50 % proti 47 %) in < 400 kopij/ml (54 % proti 57 %).
Proposed action:
Predlagani ukrepi:
Propranolol crosses the blood-brain barrier and the placenta, and is distributed into breast milk.
Propranolol prehaja skozi krvno- možgansko pregrado in placento in se porazdeli v materino mleko.
Propranolol is a beta-blocker that is characterised by three pharmacological properties:
Propranolol je antagonist adrenergičnih receptorjev beta, ki ga zaznamujejo tri farmakološke lastnosti:
Propranolol is metabolized through three primary routes: aromatic hydroxylation (mainly 4- hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucuronidation.
Propranolol se presnavlja po treh primarnih poteh: aromatska hidroksilacija (večinoma 4- hidroksilacija), N-dealkilacija, ki ji sledi oksidacija stranske verige, in neposredna glukuronidacija.
Propranolol may increase the risk of stroke in PHACE syndrome patients with severe cerebrovascular anomalies by dropping blood pressure and attenuating flow through occluded, narrow, or stenotic vessels.
Propranolol lahko poveča tveganje za možgansko kap pri bolnikihs sindromom PHACE s hudimi cerebrovaskularnimi nepravilnostmi zaradi znižanega krvnega tlaka in oslabitve pretoka skozi zamašene, zožene ali stenotične žile.
propranolol, carvedilol, timolol (used in the treatment of high blood pressure ),
propranolol, karvedilol, timolol (za zdravljenje visokega krvnega tlaka),
propranolol, carvedilol, timolol (used in the treatment of high blood pressure),
propranolol, karvedilol, timolol (za zdravljenje visokega krvnega tlaka),
Propylene carbonate Glycerol formal
Propilen karbonat Glicerol formal
Propylene glycol 9
Propilenglikol 9
Propylene glycol Ammonium hydroxide 28%
propilenglikol amonijev hidroksid 28
Propylene glycol methyl ether.
Propilenglikol metileter
Propylene glycol monocaprylate Propylene glycol dicaprylocaprate
Propilenglikol monokaprilat Propilenglikol dikaprilat/dikaprat
Propylene glycol Potassium hydroxide Black iron oxide (E172)
propilenglikol kalijev hidroksid črni železov oksid (E172)
Propylene glycol which may cause skin irritation.
propilenglikol, ki lahko povzroči draženje kože.
Propylene glycol5
Kalijev hidroksid 4
propylene glycol: May cause skin irritation.
propilenglikol: lahko povzroča draženje kože.
ProQuad - Powder in vial and solvent in pre-filled syringe with 1 unattached needle - Pack of 1, 10, 20
ProQuad – prašek v viali in vehikel v napolnjeni injekcijski brizgi z 1 nepritrjeno iglo – pakiranje po 1, 10, 20
ProQuad - Powder in vial and solvent in pre-filled syringe with 2 unattached needles - Pack of 1, 10, 20
ProQuad – prašek v viali in vehikel v napolnjeni injekcijski brizgi z 2 nepritrjenima iglama - pakiranje po 1, 10, 20
ProQuad - Powder in vial and solvent in pre-filled syringe with attached needle - Pack of 1, 10
ProQuad – prašek v viali in vehikel v napolnjeni injekcijski brizgi z iglo – pakiranje po 1, 10
ProQuad - Powder in vial and solvent in pre-filled syringe without needle - Pack of 1, 10, 20
ProQuad – prašek v viali in vehikel v napolnjeni injekcijski brizgi brez igle – pakiranje po 1, 10, 20
ProQuad - Powder in vial and solvent in vial - Pack of 1, 10
ProQuad – prašek v viali in vehikel v viali – pakiranje po 1, 10
ProQuad contains sorbitol
Cepivo ProQuad vsebuje sorbitol
ProQuad is expected to have no or negligible influence on the ability to drive and use machines.
Pri cepivu ProQuad se pričakuje, da nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
ProQuad may be administered from 9 months of age.
S cepivom ProQuad se lahko cepi v starosti od 9 mesecev dalje.
ProQuad powder and solvent for suspension for injection
ProQuad prašek in vehikel za suspenzijo za injiciranje
ProQuad powder and solvent for suspension for injection in a pre-filled syringe Measles, mumps, rubella and varicella vaccine (live)
ProQuad prašek in vehikel za suspenzijo za injiciranje v napolnjeni injekcijski brizgi cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo)
ProQuad powder and solvent for suspension for injection in a pre-filled syringe Measles, mumps, rubella and varicella vaccine (live).
ProQuad prašek in vehikel za suspenzijo za injiciranje v napolnjeni injekcijski brizgi cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo)
ProQuad powder and solvent for suspension for injection Measles, mumps, rubella and varicella vaccine (live)
ProQuad prašek in vehikel za suspenzijo za injiciranje cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo)
ProQuad should not be given to pregnant women .
Nosečnic se ne sme cepiti s cepivom ProQuad.
ProQuad was compared with its ‘component vaccines’, a triple vaccine against mumps, measles and rubella, and a vaccine against chickenpox.
Cepivo ProQuad so primerjali s „sestavljenimi cepivi“, tj. trojnim cepivom proti mumpsu, ošpicam in rdečkam, ter cepivom proti noricam.
Prospective cohort safety study protocol update to be submitted within one week of Commission Decision granting Marketing Authorization.
Posodobitev protokola prospektivne kohortne študije varnosti, ki jo je treba predložiti v roku enega tedna po odločitvi Komisije za izdajo dovoljenja za promet z zdravilom.
Prospective cohort: initiated 23 Oct
Prospektivna kohorta: začetek 23.
Prostacyclin-like associated adverse reactions
Prostaciklinu podobni povezani neželeni učinki
prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Prostaglandini so snovi, ki sprožajo vnetje, bolečino, izločanje tekočine in zvišano telesno temperaturo, meloksikam pa zmanjša obseg teh odzivov.
prostaglandins are substances that trigger inflammation, tepoxalin reduces the inflammation and the swelling of muscles or joints and the pain associated with this.
prostaglandini sprožajo vnetje, tepoksalin zmanjša vnetje in otekanje mišic ali sklepov ter bolečine, ki so povezane s tem procesom.
Prostaglandins are substances that trigger pain, swelling and inflammation, and the action of Quadrisol reduces these responses.
Prostaglandini so snovi, ki sprožijo bolečino, otekanje in vnetje, zdravilo Quadrisol pa te reakcije zmanjša.
Prostate cancer
pro pro
prostate cancer, with prednisone or prednisolone
za zdravljenje raka prostate se lahko uporablja v kombinaciji s prednizonom ali prednizolonom;
Prostate problems
težave s prostato
Prostate specific antigen (PSA) levels are lowered by 64% two weeks after administration of degarelix, 85% after one month, 95% after three months, and remained suppressed (approximately 97%) throughout the one year of treatment.
Koncentracije za prostato specifičnega antigena (PSA) se znižajo za 64 % dva tedna po aplikaciji degareliksa, za 85 % po enem mesecu, za 95 % po treh mesecih, nato pa ostanejo suprimirane (za približno 97 %) ves čas do konca prvega leta zdravljenja.
prostatic specific antigen increased
zvišana koncentracija za prostato specifičnega antigena
Prosthetic heart valves
Umetne srčne zaklopke
Prosthetic heart valves and moderate to severe mitral stenosis
Umetne srčne zaklopke in zmerna do težka mitralna stenoza
Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of edoxaban.
Ni pričakovati, da bi protaminijev sulfat in vitamin K vplivala na antikoagulacijski učinek edoksabana.
Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban.
Ni pričakovati, da bi protaminijev sulfat in vitamin K vplivala na antikoagulacijski učinek rivaroksabana.
Protamine sulfate Zinc oxide Glycerol
protaminijev sulfat cinkov oksid glicerol
Protamine sulphate m-cresol [1.76 mg/ml]
Protamin sulfat Metakrezol [1,76 mg/ml]
Protamine sulphate m-cresol [2.20 mg/ml]
Protamin sulfat Metakrezol [2,20 mg/ml]
Protamine sulphate, metacresol,
Protaminijev sulfat, metakrezol,
Protaphane 100 international units/ml suspension for injection in vial human insulin
Protaphane 100 mednarodnih enot/ml suspenzija za injiciranje v viali humani insulin
Protaphane 100 international units/ml suspension for injection.
Protaphane 100 mednarodnih enot/ml suspenzija za injiciranje
Protaphane 40 international units/ml suspension for injection in vial human insulin
Protaphane 40 mednarodnih enot/ml suspenzija za injiciranje v viali humani insulin
Protaphane 40 international units/ml suspension for injection.
Protaphane 40 mednarodnih enot/ml suspenzija za injiciranje
Protaphane can be used in children and adolescents.
Zdravilo Protaphane se lahko uporablja pri otrocih in mladostnikih.
Protaphane contains insulin mixed with another substance, protamine, in an ‘isophane’ form which is absorbed much more slowly during the day.
V zdravilu Protaphane je insulin zmešan z drugo snovjo, tj. protaminom, v obliki „izofan“, ki se čez dan absorbira mnogo počasneje.
Protaphane FlexPen 100 international units/ml suspension for injection in pre-filled pen human insulin
Protaphane FlexPen 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
Protaphane FlexPen 100 international units/ml Suspension for injection in pre-filled pen Insulin human
Protaphane FlexPen 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
Protaphane FlexPen is a pre-filled disposable pen containing human insulin as isophane (NPH).
Protaphane FlexPen je napolnjen injekcijski peresnik za enkratno uporabo, ki vsebuje humani insulin izofan (NPH).
Protaphane FlexPen is accompanied by a package leaflet with detailed instructions for use to be followed.
Zdravilu Protaphane FlexPen je priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Protaphane human insulin
Protaphane humani insulin
Protaphane InnoLet 100 international units/ml suspension for injection in pre-filled pen human insulin
Protaphane InnoLet 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
Protaphane InnoLet 100 international units/ml Suspension for injection in pre-filled pen Insulin human
Protaphane InnoLet 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
Protaphane InnoLet 100 international units/ml suspension for injection in pre-filled pen.
Protaphane InnoLet 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Protaphane InnoLet is a pre-filled disposable pen containing human insulin as isophane (NPH).
Protaphane InnoLet je napolnjen injekcijski peresnik za enkratno uporabo, ki vsebuje humani insulin izofan (NPH).
Protaphane InnoLet is accompanied by a package leaflet with detailed instructions for use to be followed.
Zdravilu Protaphane InnoLet je priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Protaphane is a human insulin with a gradual onset and long duration of action.
Zdravilo Protaphane je humani insulin z dolgodelujočim učinkom in postopnim začetkom delovanja.
Protaphane is a human insulin with gradual onset and long duration of action.
Zdravilo Protaphane je dolgodelujoči humani insulin s postopnim začetkom delovanja.
Protaphane Penfill 100 international units/ml suspension for injection in cartridge human insulin
Protaphane Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku humani insulin
Protaphane Penfill 100 international units/ml suspension for injection in cartridge.
Protaphane Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v injekcijskem vložku
Protaphane Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Zdravilu Protaphane Penfill je priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Protaphane Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles.
Zdravilo Protaphane Penfill je namenjeno za uporabo s sistemi za dajanje insulina družbe Novo Nordisk in iglami NovoFine ali NovoTwist.
Protaphane vial is accompanied by a package leaflet with detailed instructions for use to be followed.
Viali z zdravilom Protaphane je priloženo navodilo za uporabo s podrobnimi napotki za uporabo, ki jih je treba upoštevati.
Protaphane vials are for use with insulin syringes with a corresponding unit scale.
Viale z zdravilom Protaphane so namenjene uporabi z insulinskimi brizgami, ki imajo ustrezno odmerno skalo.
Protaphane vials are for use with insulin syringes with the corresponding unit scale.
Viale zdravila Protaphane so namenjene uporabi z insulinskimi brizgami, ki imajo ustrezno odmerno skalo.
Protaphane with alcohol
Zdravilo Protaphane skupaj z alkoholom
Protease inhibitor concentrations may decrease (as observed with lopinavir/ritonavir) or increase.
Koncentracije inhibitorjev proteaz
Protease Inhibitors
Zaviralci proteaz
protease inhibitors (e.g. fosamprenavir, indinavir, ritonavir, saquinavir, tipranavir);
zaviralci proteaz (npr. fosamprenavir, indinavir, ritonavir, sakvinavir, tipranavir);
Protease inhibitors (PI)
Zaviralci proteaz (PI)
Protease inhibitors (PI)
Zaviralci proteaze (ZP)
Protease Inhibitors (PI) - Boosted (with co-administration of low-dose ritonavir)
Zaviralci proteaze (PI) – okrepljeni (s sočasnim dajanjem nizkih odmerkov ritonavira)
Protease inhibitors (PIs)
Zaviralci proteaz (PI-ji)
Protease inhibitors (PIs)
Zaviralci proteaz (PI-ji):
Protease inhibitors (PIs)
Zaviralci proteaze
Protease inhibitors (PIs):
Zaviralci proteaz (PI-ji):
Protease Inhibitors (PIs): Taking Aptivus may cause large decreases in the blood levels of other HIV protease inhibitors.
Zaviralci proteaze (PI): Med jemanjem zdravila Aptivus se lahko močno znižajo ravni drugih zaviralcev proteaze HIV v krvi.
Protease inhibitors including ritonavir and its combinations with other protease inhibitors affect P-gp (either as inhibitor or as inducer).
Na P-gp vplivajo zaviralci proteaz , vključno z ritonavirjem in njegovimi kombinacijami z drugimi zaviralci proteaze (kot zaviralci ali induktorji).
Protease inhibitors including ritonavir and its combinations with other protease inhibitors affect P-gp (either as inhibitor or as inducer).
Na P-gp vplivajo zaviralci proteaze, vključno z ritonavirjem in kombinacijami ritonavirja z drugimi zaviralci proteaz (kot zaviralci ali induktorji).
Protease inhibitors including ritonavir and its combinations with other protease inhibitors affect P-gp (either as inhibitor or as inducer).
Na P-gp vplivajo zaviralci proteaze, vključno z ritonavirjem in njegovimi kombinacijami z drugimi zaviralci proteaze (kot zaviralci ali induktorji).
protease inhibitors suggest a possible 3-4
kažejo na možnost 3-4 kratnega zvečanja
protease inhibitors suggest a possible 3-4
zaviralcev proteaz kažejo na možnost 3-4
protease inhibitors that are potent
uporabo rifabutina z zaviralci proteaz, ki
protease inhibitors used in the treatment of Human Immunodeficiency Virus (HIV)
zaviralci proteaz, ki se uporabljajo za zdravljenje virusa humane imunske pomanjkljivosti (HIV),
protease inhibitors, anti-infectives such as ketoconazole, azole antifungals, clarithromycin or telithromycin. carbamazepine, rifampicine, phenobarbital, phenytoin, efavirenz or St. John’s Wort (potential risk of reduced efficacy).
zaviralce proteaz, zdravila za zdravljenje okužb, kot so ketokonazol, azolna protiglivična zdravila, klaritromicin ali telitromicin, karbamazepin, rifampicin, fenobarbital, fenitoin, efavirenz ali šentjanževko (obstaja tveganje za zmanjšano učinkovitost).
Protease inhibitors- for HIV.
Zaviralce proteaz – za HIV.
Protease inhibitors: careful monitoring for any occurrence of drug toxicity and /or lack of anti- viral efficacy, and dose adjustment if required.
Inhibitorji proteaze: skrbno spremljati vsakršen pojav toksičnih učinkov zdravila in/ali pomanjkanja učinkovitosti protivirusnega delovanja in prilagoditi odmerek, če je to potrebno.
Protease inhibitors: EVOTAZ in combination with other protease inhibitors is not recommended because co- administration may not provide adequate protease inhibitor exposure.
Zaviralci proteaz: Uporaba zdravila EVOTAZ v kombinaciji z drugimi zaviralci proteaz ni priporočljiva, saj pri sočasni uporabi morda ne bo dosežena zadostna izpostavljenost zaviralcu proteaz.
Protect from frost.
Zaščitite pred zmrzaljo.
Protect from light
Zaščitite pred svetlobo.
Protect from light.
Shranjujte zaščiteno pred svetlobo.
Protect from light.
Za zaščiteno pred svetlobo.
Protect from light.
Zaščitite pred svetlobo .
Protect other people.
Zaščita drugih ljudi
Protect the medicine and pre-filled pen against direct sunlight.
Zaščitite zdravilo in napolnjen injekcijski peresnik pred neposredno sončno svetlobo.
Protect the surface to cushion impact. (See Figure A)
Površino zaščitite za omilitev stika. (Glejte Sliko A)
protect your eyes with dark sunglasses. remember to take protective clothing and sunglasses with you to your appointment, as you will be photosensitive once the injection has been given.
oči si zavarujte s temnimi sončnimi očali, ne pozabite vzeti k zdravniku zaščitnih oblačil in sončnih očal, ker boste po aplikaciji injekcije postali občutljivi na svetlobo.
protect your eyes with dark sunglasses. remember to take protective clothing and sunglasses with you to your appointment, as you will be photosensitive once the injection has been given.
oči si zavarujte s temnimi sončnimi očali. ne pozabite vzeti k zdravniku zaščitnih oblačil in sončnih očal, ker boste po aplikaciji injekcije postali občutljivi na svetlobo.
Protect your Lyxumia pens from dust and dirt.
Peresnik Lyxumia zaščitite pred prahom in umazanijo.
Protect your Lyxumia pens from dust and dirt.
Peresnike Lyxumia zaščitite pred prahom in umazanijo.
Protect your Optiset from dust and dirt.
OptiSet je potrebno zaščititi pred prahom in umazanijo.
Protect your OptiSet from dust and dirt.
OptiSet je treba varovati pred prahom in umazanijo.
Protect your SoloStar from dust and dirt.
SoloStar zaščitite pred prahom in umazanijo.
Protection against hepatitis B infections may not be obtained until after the second dose (see section 5.1).
Zaščita pred okužbo z virusom hepatitisa B morda ne bo dosežena pred prejemom drugega odmerka (glejte poglavje 5.1).
Protection category: tight against solid bodies larger than 1 mm, but not waterproof.
Kategorija zaščite: ne prepušča trdnih delcev večjih od 1 mm, a ni odporen na vodo.
Protection lasted 22 weeks after vaccination for PCV2 and 21 weeks after vaccination for Mycoplasma hyopneumoniae.
Po cepljenju je zaščita proti virusu PCV2 trajala 22 tednov, proti bakteriji Mycoplasma hyopneumoniae pa 21 tednov.
Protection lasted 23 weeks after vaccination for PCV2 and 16 weeks after vaccination for Mycoplasma hyopneumonia.
Zaščita proti PCV2 je trajala 23 tednov po cepljenju in proti bakteriji Mycoplasma hyopneumoniae 16 tednov po cepljenju.
Protection of Eptifibatide Accord solution from light is not necessary during administration.
Med injiciranjem raztopine Eptifibatide Accord ni treba zaščititi pred svetlobo.
Protection of INTEGRILIN solution from light is not necessary during administration.
Med infundiranjem raztopine INTEGRILIN ni treba zaščititi pred svetlobo.
Protection of INTEGRILIN solution from light is not necessary during administration.
Med injiciranjem raztopine INTEGRILIN ni treba zaščititi pred svetlobo.
Protection starts four weeks after vaccination and lasts one year.
Zaščita nastopi štiri tedne
Protection starts one week after vaccination.
Zaščita se vzpostavi en teden po cepljenju.
Protection starts three weeks after vaccination and lasts for 23 weeks after vaccination for PCV2 and for 16 weeks after vaccination for Mycoplasma hyopneumoniae.
Zaščita začne učinkovati tri tedne po cepljenju in 23 tednov po cepljenju ščiti proti PCV2 in 16 tednov po cepljenju proti bakteriji Mycoplasma hyopneumoniae.
Protective Cap
Oranžni gumb
Protective effectiveness against cholera was evaluated during two mass-vaccination campaigns conducted in Mozambique (December 2003 – January 2004) and Zanzibar (February 2009 – May 2010).
Učinkovitost zaščite proti koleri so ocenili v dveh kampanjah množičnega cepljenja, ki sta potekali v Mozambiku (december 2003 – januar 2004) in Zanzibarju (februar 2009 – maj 2010).
Protective efficacy in Africa
[67,0; 87,9]
Protective efficacy of Dukoral against cholera has not been studied following repeated booster vaccination.
Učinkovitosti zaščite Dukorala po večkratnih poživitvenih cepljenjih niso raziskovali.
Protective efficacy, % (95% CI)
Učinkovitost zaščite, % (interval zaupanja 95 %)
Protective gloves must be worn at all times whilst handling the product and cleaning the measuring device.
Pri ravnanju z zdravilom in čiščenju merilne priprave je treba ves čas nositi rokavice.
Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.
Imunski odziv za zaščito proti CAV-2 pridruženi bolezni dihal bi naj trajal vsaj 3 leta.
Protective release liner Siliconised polyester film
Zaščitna plast silikonizirana poliestrska folija